News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 10:20:54 2024-04-24 am EDT			5-day change	1st Jan Change
89.4 ^CHF	+0.51%		+5.24%	+5.22%

03:20pm	Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	DP
01:56pm	NOVARTIS AG : UBS reaffirms its Buy rating	ZD

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	09:20am	DP
NOVARTIS AG : UBS reaffirms its Buy rating	07:56am	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	07:22am	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	06:45am	RE
Novartis: positive data for malaria treatment	04:18am	CF
NOVARTIS AG : JP Morgan remains Neutral	03:26am	ZD
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	01:35am	DJ
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	01:20am	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	12:42am	MT
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	12:30am	GL
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies	12:30am	CI
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	11:54pm	MT
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL
NOVARTIS : 2024 has started on a strong note; guidance upgraded	Apr. 23
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock	Apr. 23	MT